AUTHORS
Poonam Yadav, PhD, Lucas P Caeiro, PhD2, Jennifer Chapman, MD3, Ping Yang4, Ramiro Verdun, PhD5, Izidore S. Lossos, M.D.6
AFFILIATIONS
1 University of Miami, Miami, United States
2 University of Miami, Miami, United States
3 University of Miami, Miami, United States
4 University of Miami, Miami, United States
5 University of Miami, Miami, United States
6 University of Miami, Miami, United States
ABSTRACT
LIM domain only-2 (LMO2) protein is highly expressed in germinal center (GC) B lymphocytes and GC-derived lymphomas, except Burkitt lymphomas (BL) harboring c-MYC translocations. Previous studies also showed a significant association between loss of LMO2 expression and c-MYC rearrangements in other aggressive large B-cell lymphomas (LBCL) (PMID: 33988072, PMID: 32260556). Whether c-MYC regulates LMO2 expression and by what mechanism is currently unknown. To address this question, initially we aimed to validate loss of LMO2 expression in lymphomas with c-MYC translocation. We analyzed an independent cohort of 27 aggressive GC B-cell-derived lymphomas, including 11 diffuse large B-cell lymphomas (DLBCL), 11 BL, 3 high-grade B-cell lymphomas, not otherwise specified (HGBCL, NOS), and 2 double-hit (c-MYC / BCL2) HGBCL. LMO2 expression differed significantly between c-MYC-translocated and non-translocated aggressive LBCL: only 2 of 16 translocation-positive cases expressed LMO2 protein compared to 10 of 11 translocation-negative tumors (p<0.0001). Analysis of LMO2 RNA expression across multiple independent public datasets— TCGA Lymphoid Neoplasm DLBCL, single-cell RNA-seq of pediatric BL (GSE240252), and the CGCI-BLGSP cohort—consistently showed a significant inverse correlation between LMO2 and c-MYC expression (Pearson R = −0.56 to −0.32, p < 0.0001–0.0038). This relationship was also evident at a single-cell resolution using single-cell RNA-seq, where c-MYC-high and LMO2-expressing populations were largely mutually exclusive, indicating that the inverse association reflects cell-intrinsic regulation rather than population averaging. These findings suggest that absence of LMO2 may serve as a molecular marker for c-MYC translocations in GC-derived aggressive LBCL. We next examined the mechanism of this inverse correlation. To test whether c-MYC directly represses LMO2 expression, we generated DLBCL cell lines with doxycycline-inducible c-MYC overexpression (VAL, OCI-LY19) and with inducible c-MYC knockdown via shRNA (Raji, OCI-LY1). c-MYC expression significantly decreased LMO2 mRNA and protein in both cell lines, while c-MYC knockdown produced reciprocal increase in LMO2 expression, with concomitant expected changes in the known c-MYC target genes (CCND2, CCND3, AICDA, BCL6) confirming pathway specificity. Bioinformatic analysis identified three putative c-MYC-binding E-box motifs in the LMO2 promoter and luciferase reporter assays in HEK-293T and VAL cells showed that c-MYC significantly repressed wild-type LMO2 promoter activity. Individual mutation of each of the 3 putative c-MYC-binding E-box motifs partially relieved this repression, while combined mutation completely abrogated c-MYC-mediated repression. To confirm direct c-MYC binding at the LMO2 locus, we performed ChIP-qPCR using ten primer sets spanning the LMO2 promoter, transcription start site, and gene body. Following doxycycline-induced c-MYC overexpression, ChIP-qPCR in both OCI-LY19 and VAL cells revealed significant, reproducible c-MYC enrichment at the three putative c-MYC-binding canonical E-box motifs located in the LMO2 promoter, at levels comparable to the NPM1 positive control. As expected, we did not detect c-MYC binding to the SEMA4C promoter that served as a known negative control and in control-transduced cells. Using luciferase reporter assays and ChIP in lymphoma cell lines representing different aggressive LBCL subtypes, we show that c-MYC binds to these three E-box motifs in the LMO2 promoter (two near the distal promoter and one in the proximal promoter) and represses transcriptional activity, thereby reducing endogenous LMO2 mRNA and protein levels. These findings provide a mechanistic basis for the inverse association between LMO2 expression and c-MYC rearrangement observed in primary aggressive LBCL. Together with previous reports and publicly available datasets, our findings suggest that LMO2 expression by immunohistochemistry may serve as a useful surrogate marker for screening for c-MYC rearrangements, especially in laboratories not performing c-MYC FISH routinely in the work-up of aggressive LBCL.
DISCLOSURES
Poonam Yadav, PhD: No relevant conflicts of interest to declare.